EFFECT OF SULFHYDRYL COMPOUNDS AND GLUTATHIONE DEPLETION ON RAT-HEART MYOCYTE TOXICITY INDUCED BY 4-HYDROPEROXYCYCLOPHOSPHAMIDE AND ACROLEIN IN-VITRO

被引:27
作者
DORR, RT
LAGEL, K
机构
[1] The University of Arizona Arizona Cancer Center, College of Medicine, Department of Pharmacology, Tucson, AZ 85724
关键词
GLUTATHIONE; SULFHYDRYL; ALKYLATING AGENTS; HEART; CARDIOTOXICITY; CYCLOPHOSPHAMIDE;
D O I
10.1016/0009-2797(94)90091-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neonatal rat heart myocytes were used to study the acute cardiotoxic effects of cyclophosphamide (CTX) metabolites. The myocytes were equi-sensitive to 4-hydroperoxycyclophosphamide (4HPC) and acrolein in vitro with 50% inhibitory concentrations (IC50) of 123 mu M and 152 mu M, respectively. The parent compound, CTX, was inactive and the myocytes were much less sensitive to the bischloroethylamine alkylator, mechlorethamine (IC50= 1161 mu M). Cellular glutathione (GSH) levels were initially reduced and then transiently elevated following exposure to 4HPC. With acrolein, GSH levels were reduced to unmeasurable levels at all time points. With the addition of 0.5 mM L-buthionine sulfoximine (BSO), myocyte GSH levels were reduced from control values of 120 nmol/mg protein to < 10 nmol/mg protein without causing direct cytotoxicity. However, pretreatment with BSO significantly enhanced the cardiotoxic effects of 4HPC. Finally, two exogenous sulfhydryl-containing compounds were shown to block the myotoxic effects of both 4HPC and acrolein. Mesna and N-acetylcysteine increased at concentrations of 0.01 mu g/ml and 0.1 mu g/ml roughly increased the IC50 of 4HPC by 2-3-fold. These results suggest that acrolein and 4HPC are equipotent cytotoxins and that a transient depletion in GSH accompanies this toxic effect in cardiac myocytes.
引用
收藏
页码:117 / 128
页数:12
相关论文
共 44 条
[1]  
APPELBAUM FR, 1976, LANCET, V1, P58
[2]  
AYASH LJ, 1992, J CLIN ONCOL, V10, P996
[3]   INACTIVATION OF GLUTATHIONE REDUCTASE BY 2-CHLOROETHYL NITROSOUREA-DERIVED ISOCYANATES [J].
BABSON, JR ;
REED, DJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1978, 83 (02) :754-762
[4]  
BECK J T, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P332
[5]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[6]   CYCLOPHOSPHAMIDE CARDIOTOXICITY IN BONE-MARROW TRANSPLANTATION - A PROSPECTIVE EVALUATION OF NEW DOSING REGIMENS [J].
BRAVERMAN, AC ;
ANTIN, JH ;
PLAPPERT, MT ;
COOK, EF ;
LEE, RT .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) :1215-1223
[7]  
BROCK N, 1977, Zeitschrift fuer Krebsforschung und Klinische Onkologie, V88, P185
[8]  
BUCKNER CD, 1972, CANCER, V29, P357, DOI 10.1002/1097-0142(197202)29:2<357::AID-CNCR2820290215>3.0.CO
[9]  
2-M
[10]  
CARMICHAEL J, 1986, CANCER RES, V46, P735